The Alphabet and Dell-backed cloud security software provider saw its stock more than double on the first day of trading and now has a market cap of almost $3.9bn.

Cancer immunotherapy developer Arcus Biosciences will float at the top of its range, scoring an exit for Stanford University.

Cancer immunotherapy developer Arcus Biosciences will float at the top of its range, scoring exits for Alphabet, Novartis, Celgene and Taiho.

Existing backer Salesforce Ventures has agreed to invest a further $100m in the cloud collaboration platform through a private placement.

ETH Zurich spinout Sensirion hopes to capture $58m by going public later this month in an offering that will position co-founders Felix Mayer and Moritz Lechner as anchor shareholders.

The diabetes treatment developer will target at least $400m from a Hong Kong offering that will allow WuXi PharmaTech to exit.

Lundbeck and Novo-backed nausea and vomiting therapy developer Acacia Pharma raised $49.6m in its initial global offering in Brussels.

The immuno-oncology therapy developer, which is backed by Novo, Sanofi, EMS and Seattle Genetics, has raised $77m in venture funding.

The corporate-backed ride hailing platform, currently valued at $5bn, has met with Indonesia Stock Exchange's CEO to discuss an initial public offering.

The anime streaming platform has raised more than $510m from investors including Tencent and Legend Capital.